Data from: Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis

Gastric cancer is the second most common cause of cancer-related mortality worldwide. Accurate prediction of disease progression is difficult, and new biomarkers for clinical use are essential. Recently, we reported that the proteasome-associated deubiquitinating enzyme UCHL5/Uch37 is a new prognostic marker in both rectal cancer and pancreatic ductal adenocarcinoma. Here, we have assessed by immunohistochemistry UCHL5 tumor expression in gastric cancer. The study cohort comprised 650 patients, who underwent surgery in Helsinki University Hospital, Finland, between 1983 and 2009. We investigated the association of cytoplasmic UCHL5 tumor expression to assess clinicopathological parameters and patient survival. Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p = 0.025), and age 66 years or older (p = 0.037). UCHL5 is thus a potential marker in gastric cancer with new prognostic relevance.胃癌是全球范围内癌症相关死亡的第二大常见病因。准确预测疾病进展难度较大，临床亟需实用的新型生物标志物。近期本团队已有研究表明，蛋白酶体相关去泛素化酶（proteasome-associated deubiquitinating enzyme）UCHL5/Uch37可作为直肠癌与胰腺导管腺癌的新型预后标志物。本研究通过免疫组织化学（immunohistochemistry）法检测胃癌组织中UCHL5的肿瘤表达情况，研究队列纳入1983年至2009年间于芬兰赫尔辛基大学医院接受手术治疗的650例患者，旨在分析肿瘤细胞质UCHL5表达与临床病理参数及患者生存状况的关联。结果显示，肿瘤细胞质UCHL5免疫表达阳性与肿瘤直径小于5 cm（p=0.001）、临床分期I-II期（p=0.025）以及年龄≥66岁（p=0.037）的胃癌患者更长的生存期显著相关。综上，UCHL5有望成为胃癌的新型预后相关标志物。